IQ-AI Limited (GB:IQAI) has released an update.
IQ-AI Limited has filed a provisional patent for a cancer treatment and anticipates a significant revenue increase this year, driven by its software solutions. The company expects total revenue to reach between $900,000 and $1 million, a rise from last year’s $760,000. Additionally, IQ-AI is in talks with potential partners to fund a phase 2 clinical trial.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.
